HER-2阳性早期乳腺癌辅助治疗的研究进展  

Research progress of adjuvant therapy for HER-2 positive early breast cancer

作　　者：饶彬[1] 吴耀忠[1] 

机构地区：[1]梧州市红十字会医院普外二科,543002

出　　处：《国际医药卫生导报》2017年第6期926-928,共3页International Medicine and Health Guidance News

摘　　要：人表皮生长因子受体-2（HER-2）阳性乳腺癌是具有较强侵袭性、预后较差的一类肿瘤，曲妥珠单抗抗Her-2靶向的问世，改变了Her-2阳性乳腺癌的预后。除了曲妥珠单抗这个药物，一系列抗Her-2靶向治疗药物的相继用于临床研究及治疗，包括小分子酪氨酸激酶抑制剂拉帕替尼、来那替尼；抗Her-2分子异源二聚化的药物帕妥珠单抗以及曲妥珠单抗-细胞毒性的共轭药物（T—DM1）。本文就是对HER-2阳性早期乳腺癌的辅助治疗进行综述评价。Human epidermal growth factor receptor -2 （HER-2） - positive breast cancer is a kind of tumor with strong invasiveness and poor prognosis. Trastuzumab anti Her-2 targeted drugs has changed the prognosis of Her-2 positive breast cancer. In addition to the drug trastuzumab, a series of anti-Her-2 targeted drugs have been used in clinical research and treatment, including small molecule tyrosine kinase inhibitor （lapatinib and neratinib）, anti-Her-2 molecular heterodimerization drug （pertuzumab）, and cell toxicity of trastuzumab conjugated drug （T-DMI）. This article is to review the treatment of HER-2 positive early breast cancer.

关 键 词：人表皮生长因子受体-2 乳腺癌 曲妥珠单抗 帕妥珠单抗 拉帕替尼 

分 类 号：R737.9[医药卫生—肿瘤]